Betterlife issues 2.15M shares in debenture conversion

Executive Summary

• Betterlife Pharma Inc. converted convertible debentures totaling $215,320.55 into equity, issuing 2,153,205 common shares and an equal number of share purchase warrants.
• Each warrant allows the holder to purchase one common share at a fixed exercise price of $0.10, with expiration dates ranging from September 27 2026 to October 29 2026.
• The conversion expands the company’s outstanding equity base while providing potential future upside through the warrants.

Key Details

• Conversion amount: Principal and accrued interest on convertible debentures equal to $215,320.55 were converted into common equity.
• Shares issued: 2,153,205 newly issued common shares were issued to the debenture holders as part of the conversion.
• Warrants issued: 2,153,205 share purchase warrants were also issued; each warrant entitles the holder to acquire one additional common share at an exercise price of $0.10 per share.
• Warrant expiration: Warrants will expire between September 27 2026 and October 29 2026 (specific dates vary by warrant).
• Impact on capital structure: The conversion increases the total number of outstanding shares and introduces a pool of warrants that could further dilute existing shareholders if exercised.

Notable Quotes

(No executive quotes were provided in the release.)